Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2004

01-06-2004

Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction

Authors: Ajay J. Kirtane, Anh Bui, Sabina A. Murphy, Dimitrios Karmpaliotis, Ioanna Kosmidou, Keith Boundy, Aref Rahman, Duane S. Pinto, Julian M. Aroesty, Robert P. Giugliano, Christopher P. Cannon, Elliott M. Antman, C. Michael Gibson

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2004

Login to get access
Metadata
Title
Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction
Authors
Ajay J. Kirtane
Anh Bui
Sabina A. Murphy
Dimitrios Karmpaliotis
Ioanna Kosmidou
Keith Boundy
Aref Rahman
Duane S. Pinto
Julian M. Aroesty
Robert P. Giugliano
Christopher P. Cannon
Elliott M. Antman
C. Michael Gibson
Publication date
01-06-2004
Publisher
Kluwer Academic Publishers
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2004
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1023/B:THRO.0000040486.10549.f6

Other articles of this Issue 3/2004

Journal of Thrombosis and Thrombolysis 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine